Drug Approval | January 05, 2026
FDA delays Corcept’s hypertension drug, seeks more evidence
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
